Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2017
NICE approval for nivolumab provides new treatment for advanced blood cancer
26 July 2017 - People with an advanced type of blood cancer will benefit from nivolumab on the NHS following approval ...
Posted by Michael Wonder on 19 Jul 2017
NICE approves more tolerable treatment for blood cancer
19 July 2017 - Around 2,200 patients a year with multiple myeloma are set to benefit from a new, tolerable treatment ...
Posted by Michael Wonder on 10 Jul 2017
A new treatment option for people with kidney cancer
10 July 2017 - People with advanced kidney cancer are set to benefit from a new treatment, after NICE has ...
Posted by Michael Wonder on 05 Jul 2017
Pfizer facing NICE showdown over leukaemia drug
3 July 2017 - Pfizer’s Besponsa leukaemia drug has been approved in Europe, but the company is heading for a ...
Posted by Michael Wonder on 05 Jul 2017
Merck’s Keytruda, Lilly’s Lartruvo available via CDF
5 July 2017 - Patients with certain forms of lung cancer or sarcoma have now gained access to two new ...
Posted by Michael Wonder on 05 Jul 2017
NICE terminates another three cancer medicine assessments
5 July 2017 - This brings the number of terminated assessments for 2017 to nine. ...
Posted by Michael Wonder on 28 Jun 2017
NICE backs Afinitor, Sutent for neuroendocrine tumours
28 June 2017 - Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care ...
Posted by Michael Wonder on 28 Jun 2017
Cancer Drugs Fund driving early access to promising new treatments
28 June 2017 - NHS patients in England are getting early access to new drugs for lung cancer and sarcoma, ...
Posted by Michael Wonder on 15 Jun 2017
'Monumental U-turn' on cancer drug
15 June 2017 - A pioneering and life-extending drug repeatedly deemed too expensive will now be offered on the NHS ...
Posted by Michael Wonder on 15 Jun 2017
Kadcyla new deal for breast cancer patients given green light in final draft guidance
15 June 2017 - A new deal on the breast cancer drug Kadcyla (trastuzumab emtansine) means that it can now be ...
Posted by Michael Wonder on 14 Jun 2017
NICE publishes multiple outcomes for Adcetris
14 June 2017 - NICE has published a Final Appraisal Consultation document for patients with Hodgkin's lymphoma and an Appraisal ...
Posted by Michael Wonder on 13 Jun 2017
Amgen’s myeloma treatment Kyprolis gains NICE approval
13 June 2017 - NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself ...
Posted by Michael Wonder on 13 Jun 2017
NICE publishes appraisal consultation document for inotuzumab ozogamicin
13 June 2017 - The Department of Health has asked NICE to produce guidance on the use inotuzumab ozogamicin in the ...
Posted by Michael Wonder on 12 Jun 2017
Olaratumab recommended for NHS use in England
12 June 2017 - Lartruvo (olaratumab), in combination with doxorubicin, has been recommended by the medicines cost-effectiveness watchdog for England ...
Posted by Michael Wonder on 02 Jun 2017
NICE backs Opdivo for classical Hodgkin lymphoma
2 June 2017 - Patients with classical Hodgkin lymphoma living in England and Wales could now become the first to ...